You just read:

Roche's VENTANA PD-L1 (SP263) Assay gains CE label expansion to inform treatment decisions in lung cancer patients being considered for KEYTRUDA (pembrolizumab) immunotherapy

News provided by

Roche

05 May, 2017, 18:37 BST